| AE | Adverse event |
| ARDS | Acute respiratory distress syndrome |
| BCMA | B-cell maturation antigen |
| BID | Twice daily |
| CAR | Chimeric antigen receptor |
| CI | Confidence interval |
| COVID-19 | Coronavirus disease 2019 |
| CRP | C-reactive protein |
| EV | Extracellular vesicle |
| GPRC5D | G protein-coupled receptor family C group 5 member D |
| IFN | Interferon |
| IL | Interleukin |
| ITT | Intention-to-treat |
| JAK | Janus kinase |
| MHC | Major histocompatibility complex |
| miRNA | MicroRNA |
| MM | Multiple myeloma |
| MSC | Mesenchymal stem cell |
| NK | Natural killer |
| PCR | Polymerase chain reaction |
| RR | Relative risk |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| sEV | Small extracellular vesicle |
| TGF-β | Transforming growth factor-beta |
| TNF | Tumor necrosis factor |
| VFD | Ventilator-free days |